MedTrace Logo

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

NCT05692024 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-05

No results posted yet for this study

Summary

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.

Conditions

  • Colorectal Cancer
  • Coffee
  • Gastrointestinal Microbiome
  • Stenosis
  • Fibrosis, Liver
  • Ultrasound Elastography
  • Proton Magnetic Resonance Spectroscopy

Interventions

DRUG

Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.

Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.

DRUG

Placebo

Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.

Sponsors & Collaborators

Principal Investigators

  • Aparna R Parikh, MD, MS · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-21
Primary Completion
2028-03-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05692024 on ClinicalTrials.gov